Abstract
Abstract: :
Purpose: Intraocular lens implantation in patients with uveitis is widely accepted, but the ideal material is yet to be discovered. We evaluated the visual outcome and biocompatibility of an injectable, single piece, posterior chamber hydrophilic acrylic intraocular lens implant following phakoemulsfication in patients with uveitis. Methods: Retrospective analysis of 100 consecutive eyes of 84 patients with various types of uveitis who underwent phakoemulsfication cataract extraction with implantation of Rayner 570H or 574H injectable, hydrophilic, acrylic, posterior chamber IOL by a single surgeon. All eyes were free of active inflammation at time of surgery. We looked at the rate of visual acuity change and for posterior synechiae, giant cells on the optic and posterior capsular opacification (PCO). Results: There were 23 males and 61 females with a mean age of 57.8 years (range 25–96). Mean follow up was 29 months (range 5–60 months). 47 patients had anterior, 1 intermediate and 52 had panuveitis. There was a 90% improvement in visual acuity compared with preoperative levels; 74% seeing 6/12 or better. The main cause for reduced visual acuity was pre–existing macular oedema or scar. 89.5% of eyes with preoperative posterior synechiae (PS) remained free of PS postoperatively. On follow up 2% of eyes had anterior capsular phimosis, 42% had posterior capsular opacification of whom only 6 eyes needed Nd:YAG capsulotomies. None of the eyes had surface pigmentation or scratch marks on the IOL. Conclusions: Hydrophilic acrylic intraocular implants appear safe to implant in patients with uveitis. They are associated with an excellent postoperative visual outcome and absence of significant IOL deposits or postoperative inflammation.
Keywords: clinical (human) or epidemiologic studies: outcomes/complications • treatment outcomes of cataract surgery • uveitis-clinical/animal model